View Post

Junjie Li, MD, on Capecitabine in Triple-Negative Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Jeff Minerd From: Clinical trial focused exclusively on TNBC patients Current breast cancer treatment guidelines suggest that capecitabine (Xeloda) should be considered for adjuvant treatment after standard neoadjuvant therapy with taxane- and anthracycline-based chemotherapy. However, although randomized trials have evaluated capecitabine as adjuvant treatment in breast cancer overall as well as in elderly patients, none have focused solely …